Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared a post on X:
“Neoadjuvant THP x12 will likely soon become a SoC for many patients with stage II HER2+ breast cancer. While awaiting confirmation from the CompassHER2-pCR trial, DAPHNe provides a glimpse of the future
- 96% ultrasensitive ctDNA clearance
- 5y RFI 98%.”
Title: Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial
Authors: Paolo Tarantino, Tianyu Li, Esther Ritah Ogayo, Tasnim Rahman, Molly K. DiLullo, Ashka Patel, Sherif El-Refai, Charles Abbott, Bailiang Li, Sean M. Boyle, Richard O. Chen, Neelam V. Desai, Laura M. Spring, Nadine M. Tung, Natalie Sinclair, Meredith Faggen, Michael Constantine, Tari A. King, Ian E. Krop, Nabihah Tayob, Elizabeth A. Mittendorf, Sara M. Tolaney, Eric P. Winer, Heather A. Parsons, Adrienne G. Waks
Read the Full Article.
Can 12 Weeks of THP Be Enough for Some Patients With Early HER2-Positive Breast Cancer?
